High Signatera Result: What the Numbers Mean

A high Signatera result means the test has detected circulating tumor DNA (ctDNA) in your blood, and the measured level is elevated. Signatera reports results in a unit called mean tumor molecules per milliliter of plasma (MTM/mL), and a higher number signals a greater burden of tumor-derived DNA fragments circulating in your bloodstream. But a single number on a lab report doesn’t tell the whole story. What matters clinically is whether the result is positive or negative, how high the level is relative to prior draws, and whether the trend is rising or falling over time.

What Signatera Actually Measures

Signatera is a personalized, tumor-informed ctDNA test. Unlike broad cancer screening tools, it starts by analyzing your own tumor tissue to identify a set of mutations unique to your cancer. It then looks for those specific mutations in a simple blood draw. The result is reported as a concentration in MTM/mL. A result of 0.00 MTM/mL means no tumor DNA was detected, which the report calls “negative” or “not detected.” Any value above zero is “positive,” meaning tumor-derived DNA fragments were found.

The test is designed for monitoring after surgery or during treatment, not for initial cancer diagnosis. Its main use is detecting minimal residual disease (MRD), the small amounts of cancer that may remain after a tumor has been removed, and flagging recurrence earlier than imaging can. Because it tracks mutations unique to your tumor, its specificity is high. One head-to-head comparison found that tumor-informed ctDNA testing had a specificity of about 99%, meaning false positives are rare.

What a Positive Result Means for Recurrence Risk

A positive Signatera result after surgery is one of the strongest signals available that cancer may come back. Across multiple cancer types, detection of ctDNA after curative-intent surgery is associated with dramatically higher recurrence risk compared to a negative result. In colorectal cancer, a large meta-analysis found that patients who tested ctDNA-positive after surgery had roughly seven times the recurrence risk of those who tested negative.

That ratio isn’t unique to colorectal cancer. In liver cancer, a meta-analysis of ten studies found that postoperative ctDNA positivity roughly quadrupled the risk of shorter recurrence-free survival.

In head and neck cancer, a positive postoperative ctDNA result carried a hazard ratio of about 7.5 for recurrence, while conventional risk groupings failed to reach significance.

⁴

The picture is consistent: across solid tumors, a positive result after surgery is a red flag that residual disease likely remains, even when scans look clean.

Does a Higher Number Mean Worse Odds

Yes, but with an important caveat. Signatera is primarily designed as a qualitative call: positive or negative. The MTM/mL value gives you a quantitative dimension on top of that, and emerging research suggests higher concentrations do carry worse prognoses. In one breast cancer study, researchers split patients into groups based on whether their ctDNA concentration was above or below a median of about 19.6 MTM/mL. Patients with levels above that threshold had significantly shorter recurrence-free survival.

⁵

That said, there is no universally agreed-upon cutoff that separates “a little concerning” from “very concerning.” The absolute number depends on your cancer type, tumor biology, how much DNA your particular cancer sheds, and when the blood was drawn relative to surgery. A reading of 5 MTM/mL in one patient might carry a different weight than 5 MTM/mL in another. Your oncologist interprets the number in the context of your full clinical picture, not in isolation.

Why the Trend Matters More Than Any Single Number

If you’ve had multiple Signatera tests, the trajectory of results over time is often more informative than any single reading. A level that was undetectable and is now climbing signals new or growing disease. A level that was positive and is falling, especially after treatment, suggests treatment is working. A reading that clears to zero and stays there is the most reassuring pattern.

In melanoma, longitudinal ctDNA trends proved more reliable than looking at individual timepoints. Rising or persistently positive ctDNA preceded radiologic evidence of disease progression by a median of about 11 months.

⁶

A published case in colon cancer illustrates how a rising trend can be actionable: a patient’s ctDNA rose after surgery, prompting an early PET/CT that revealed a single liver metastasis treatable with curative-intent surgery. After the metastasis was removed, ctDNA cleared to 0.00 MTM/mL and stayed there.

⁷

Clearance of ctDNA during treatment also has prognostic value. A meta-analysis in advanced lung cancer found that patients whose ctDNA cleared during targeted therapy had substantially longer progression-free and overall survival than those whose ctDNA persisted.

⁸

How Far Ahead of Scans Can Signatera Detect Recurrence

One of the biggest practical advantages of ctDNA monitoring is lead time: it can flag recurrence months before a CT scan or MRI shows anything. In a large breast cancer study using serial Signatera testing, ctDNA was detected ahead of clinical or radiologic relapse in about 88% of patients who eventually recurred. The median lead time was 10.5 months, and in some patients ctDNA was positive more than three years before imaging caught up.

⁹

That doesn’t mean every positive result will be followed by visible disease on a scan right away. In fact, the gap between molecular detection and imaging detection is the whole point. Some patients with rising ctDNA will eventually develop a scannable lesion; others, especially those who receive treatment escalation based on the molecular signal, may never reach that point. The lead time creates a window of opportunity where treatment decisions can potentially be made earlier.

Signatera vs. Traditional Blood Markers Like CEA

Many cancer patients are already familiar with older blood tests such as CEA (carcinoembryonic antigen) or CA 19-9. These conventional markers have been around for decades, but they have well-known limitations. In non-small cell lung cancer, one study found that longitudinal CEA monitoring had a sensitivity of only about 49%, and a third of patients with progressively rising CEA levels were actually disease-free.

¹⁰

In biliary tract cancer, a real-world analysis found that ctDNA positivity during surveillance was the strongest prognostic factor for recurrence-free survival, with a hazard ratio above 8. By contrast, neither CA 19-9 nor CEA provided significant predictive value for recurrence or overall survival.

¹¹

The difference comes down to specificity. CEA and CA 19-9 can rise for reasons completely unrelated to cancer, from inflammation to smoking to benign liver conditions. Signatera tracks mutations that are unique to your tumor, so a positive result is far less likely to be a false alarm. If your oncologist is tracking both, the Signatera result generally carries more clinical weight.

How Results Influence Treatment Decisions

For many patients, the most pressing question after getting a high Signatera result is: what happens next? In colorectal cancer, ctDNA results are increasingly being used to guide whether patients receive adjuvant chemotherapy after surgery. In one large prospective analysis, patients with stage II or III colorectal cancer who tested ctDNA-positive after surgery had tenfold the recurrence risk. Critically, those positive patients appeared to benefit substantially from adjuvant chemotherapy.

¹²

The BESPOKE CRC study added another layer of evidence. Among patients who were MRD-positive, those who received adjuvant chemotherapy had a median disease-free survival of about 19 months, compared to roughly 7 months for those who were observed without treatment. Among MRD-negative patients, chemotherapy showed no benefit at all.

¹³

This creates a practical framework: a positive result can push treatment toward chemotherapy that the patient may genuinely need, while a negative result can provide justification for skipping chemotherapy that probably wouldn’t help. A cost-effectiveness analysis concluded that adding ctDNA-based MRD testing to standard clinical and pathological predictors is likely cost-effective in the U.S. healthcare system for guiding these decisions.

¹⁴

When a Positive Result Can Be Misleading

A positive Signatera result is not a guarantee that cancer is actively growing. Although the test’s specificity is very high, no molecular test is perfect. There are a few situations where context matters:

Timing after surgery: Blood drawn too soon after an operation may still contain tumor DNA shed during the surgical process itself. Most study protocols collect samples four to ten weeks post-surgery to allow clearance of residual surgical debris.

¹⁵

Low-level transient positivity: Occasionally, a very low positive reading may not persist on the next draw. A single low-positive result, especially without a rising trend, is less alarming than a persistently or increasingly positive one.
Tumor shedding variation: Not all cancers shed DNA into the bloodstream at the same rate. Factors like tumor location, size, vascularity, and histological type all influence how much ctDNA enters circulation.

¹⁶

On the other side, a negative result doesn’t guarantee you’re cancer-free. The test’s sensitivity, while strong, is not 100%. In one early-stage lung cancer comparison, tumor-informed ctDNA testing picked up about two-thirds of cases with detectable residual disease.

That means roughly a third of patients with residual disease had a false-negative result. Some small or slow-growing tumors simply don’t shed enough DNA to be caught. This is why oncologists use Signatera alongside imaging and clinical assessment, not as a standalone oracle.

The Emotional Weight of a ctDNA Result

Getting a cancer blood test result hits differently than most lab work. A qualitative study of colorectal cancer survivors who underwent ctDNA testing found that negative results generally brought relief and reassurance, but positive results triggered a wide range of emotional responses, from acute distress to a more pragmatic sense that the result validated their decision to pursue additional treatment.

¹⁷

Interestingly, many patients in that study had limited recall of the specific ctDNA numbers. What stuck with them was the binary: positive or negative. This mirrors how most oncologists communicate results. The detailed MTM/mL value matters for tracking trends over time and for clinical decision-making, but for the patient sitting in the exam room, the first and most important piece of information is whether tumor DNA was found.

If you’ve received a positive result and are struggling with the uncertainty it creates, it helps to remember what the number represents: an early warning system, not a verdict. Many patients with positive ctDNA results go on to receive effective treatment precisely because the test flagged residual disease before it had a chance to grow into something harder to treat.

Dozens of Trials Are Reshaping How These Results Are Used

Signatera and similar ctDNA tests are still in a period of rapid clinical evolution. A review of the trial landscape identified 57 phase II and III trials focused on using ctDNA for minimal residual disease detection and treatment guidance, with the pace of new trial initiation accelerating in recent years.

¹⁸

Some of these trials are testing escalation strategies, giving additional therapy to ctDNA-positive patients who might otherwise have been observed. Others are testing de-escalation, sparing ctDNA-negative patients from chemotherapy they were traditionally expected to receive. The results of these trials will determine whether ctDNA-guided treatment becomes the standard of care or remains an adjunct to existing protocols. For now, your oncologist may use the result as one input among many, or, depending on the cancer type and the institution, as a central factor in the treatment plan.

What’s already clear is that the field is moving toward a model where a blood test taken weeks after surgery provides information that previously required months of anxious waiting and serial imaging. For patients navigating this territory, understanding that a high Signatera number is an actionable signal, not just a number to worry about, can reframe the experience from one of helplessness to one where early detection translates into early intervention.